Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX +0.37%22 Return-on-Tangible-Asset is 17.75% as of Mar. 2026, which is 30% below its 10-year median of 25.23. GuruFocus rates NSE:INFLUX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Influx Healthtech ranks better than 93.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Influx Healthtech's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹211 Mil. Influx Healthtech's average total tangible assets for the quarter that ended in Mar. 2026 was ₹1,186 Mil. Therefore, Influx Healthtech's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 17.75%.
The historical rank and industry rank for Influx Healthtech's Return-on-Tangible-Asset or its related term are showing as below:
NSE:INFLUX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 20.04 Med: 25.23 Max: 32.09
Current: 20.04
During the past 5 years, Influx Healthtech's highest Return-on-Tangible-Asset was 32.09%. The lowest was 20.04%. And the median was 25.23%.
NSE:INFLUX's Return-on-Tangible-Asset is ranked better than 93.84% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.94
vs NSE:INFLUX: 20.04
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Influx Healthtech Return-on-Tangible-Asset Related Terms
Influx Healthtech Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 17.75% mean?
Influx Healthtech (NSE:INFLUX) has a Return-on-Tangible-Asset of 17.75% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Influx Healthtech and its competitors. This is 30% below median its historical median of 25.23. Over the past decade, Influx Healthtech's Return-on-Tangible-Asset has ranged from 20.04 to 32.09. According to the industry distribution chart, Influx Healthtech ranks #62 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is Influx Healthtech's Return-on-Tangible-Asset too high?
Influx Healthtech's current Return-on-Tangible-Asset of 17.75% is 30% below median its 10-year median of 25.23. Over the past 10 years, this metric has ranged from a low of 20.04 to a high of 32.09. The Drug Manufacturers industry median Return-on-Tangible-Asset is 2.94. Influx Healthtech's value of 17.75% is 503.7% above this industry median. Based on the distribution chart, Influx Healthtech ranks #62 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #62 out of 1007 companies for Return-on-Tangible-Asset. This places Influx Healthtech in the top 6% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.94. Influx Healthtech's value of 17.75% is 503.7% above this benchmark. Historically, Influx Healthtech's own Return-on-Tangible-Asset has ranged from 20.04 to 32.09 over the past decade. While the company's 10-year median is 25.23 vs. the industry median of 2.94, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 2.94, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current Return-on-Tangible-Asset of 17.75% is 503.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current Return-on-Tangible-Asset is 17.75%, which is 30% below median its own 10-year median of 25.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Return-on-Tangible-Asset of 17.75%. The current Return-on-Tangible-Asset is 17.75%, which is 30% below median its 10-year median of 25.23 and 503.7% above the Drug Manufacturers industry median of 2.94. Influx Healthtech's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Return-on-Tangible-Asset is 17.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
22GF Score
Get the complete analysis for NSE:INFLUX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
